Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is a biotech company with a strong focus on developing innovative treatments for brain tumors. Its lead drug, NEO212, has shown promising results in clinical trials and the company's financials have improved. With the potential success of NEO100 and the use of Perillyl Alcohol, NeOnc has a solid opportunity to improve the treatment options for patients with difficult-to-treat central nervous system diseases.

Bears say

NeOnc Technologies Hldgs is facing potential technical risks with its complex drug dosing, potentially causing delays in its pipeline molecules reaching the market. Furthermore, the company's drugs may have potential safety risks for patients due to chronic disruption of nasal epithelial integrity. The company's data for its lead candidates is limited, and the slow enrollment in clinical trials may delay potential market entry. Overall, it remains to be seen if the company's drug delivery methods can prove effective in penetrating the CNS and achieving positive clinical outcomes, and more comprehensive data is needed for a clearer outlook on the company's potential.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Jun 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.